Adenosine monophosphate-activated protein kinase (AMPK), a central regulator of cellular energy homeostasis, ameliorates NAFLD-related lipid metabolic imbalance and liver injury by phosphorylating downstream target proteins (e.g., ACC, mTOR, SREBP-1c). Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.